Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Launched by CASE COMPREHENSIVE CANCER CENTER · Nov 18, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Determine the incidence and types of acute complications in patients undergoing stereotactic radiosurgery for brain tumors or other brain disorders.
* Determine the time frame for development and resolution of these complications in these patients.
* Determine the severity of these complications in these patients.
OUTLINE: Patients undergo stereotactic radiosurgery. Patients also complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
PROJECTED ACC...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- * Diagnosis of brain tumor or other brain disorder, including, but not limited to, 1 of the following:
- • Primary brain tumors
- • Brain metastases
- • Acoustic neuromas
- • Pituitary adenomas
- • Parkinson's disease
- • Cluster headaches
- • Glomus jugulare
- • Epilepsy
- • Obsessive compulsive disorder
- • Arteriovenous malformations
- • Trigeminal neuralgia
- • Eligible for and scheduled to undergo stereotactic radiosurgery
- PATIENT CHARACTERISTICS:
- • Performance status
- • Not specified
- • Life expectancy
- • Not specified
- • Hematopoietic
- • Not specified
- • Hepatic
- • Not specified
- • Renal
- • Not specified
- • Other
- • No physical or mental limitation that would preclude study compliance
- PRIOR CONCURRENT THERAPY:
- • Endocrine therapy
- • Concurrent steroids allowed
- • Radiotherapy
- • No prior stereotactic radiosurgery
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is a leading academic research institution dedicated to advancing cancer care through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates multidisciplinary approaches to cancer prevention, diagnosis, and treatment, fostering collaboration among clinicians, researchers, and patients. The center is committed to translating scientific discoveries into effective therapies, enhancing patient outcomes, and contributing to the global body of cancer knowledge. With a robust portfolio of clinical trials, Case Comprehensive Cancer Center aims to address the unmet needs of cancer patients and drive progress in the fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
John Suh, MD
Principal Investigator
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials